Entrectinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 63 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Entrectinib - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B, and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibition of...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B, and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B, and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1, and ALK are overexpressed in a variety of cancer cell types.

Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK) and ROS1 that is used to treat solid tumors with NTRK gene fusion and non-small cell lung cancer with ROS1 mutations. Serum aminotransferase elevations are common during therapy but the clinically apparent liver injury is rare, although it has been reported.

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors. Entrectinib’s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefits over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.[rx] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors.[rx] Entrectinib’s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefits over similar ALK inhibitors such as alectinib, ceritinib, and lorlatinib due to a wider range of targets.[rx]

Mechanism of Action

Entrectinib is a tyrosine kinase inhibitor that acts on several receptors. It functions as an ATP competitor to inhibit tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC, as well as proto-oncogene tyrosine-protein kinase ROS1 and anaplastic lymphoma kinase (ALK). TRK receptors produce cell proliferation via downstream signaling through the mitogen-activated protein kinase, phosphoinositide 3-kinase, and phospholipase C-γ. ALK produces similar signaling with the addition of downstream JAK/STAT activation. Inhibition of these pathways suppresses cancer cell proliferation and shifts the balance in favor of apoptosis resulting in the shrinking of tumor volume.

Indications

  • Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available.
  • Rozlytrek as monotherapy is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options.
  • Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced nonsmall cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
  • Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK) and ROS1 that is used to treat solid tumors with NTRK gene fusion and non-small cell lung cancer with ROS1 mutations.
  • Metastatic Non-Small Cell Lung Cancer
  • Solid Metastatic Tumor
  • Solid Tumors

In the US, entrectinib is indicated to treat patients whose cancers are ROS1-positive (have a specific genetic feature (biomarker)).[rx] It is to be used in those with solid tumors that:[rx]

  • are caused by certain abnormal neurotrophic tyrosine receptor kinase (NTRK) genes, and
  • have spread or if surgery to remove their cancer is likely to cause severe complications, and
  • there is no acceptable treatment, or the cancer grew or spreads on other treatment

Entrectinib is not approved for use in those less than twelve years of age.

In the European Union, entrectinib as monotherapy is indicated for the treatment of adults and adolescents twelve years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,[rx]

  • who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and[rx]
  • who have not received a prior NTRK inhibitor[rx]
  • who have no satisfactory treatment options?[rx]

It is also indicated for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.[rx]

Use in Cancer

Entrectinib is approved to treat:

  • Non-small cell lung cancer that is ROS1 positive. It is used in adults whose cancer has metastasized (spread to other parts of the body).
  • Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins. It is used in adults and in children aged 12 years or older whose cancer has metastasized or cannot be removed by surgery and has gotten worse after other treatments or cannot be treated with other therapies.¹

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that entrectinib provides a clinical benefit in these patients.

Entrectinib is also being studied in the treatment of other types of cancer.

Contraindications

  • low amount of magnesium in the blood
  • low amount of calcium in the blood
  • low amount of potassium in the blood
  • chronic heart failure
  • abnormal EKG with QT changes from birth
  • liver problems
  • high amount of uric acid in the blood
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: 100 mg; 200 mg

Non-Small Cell Lung Cancer

  • 600 mg orally once a day until disease progression or unacceptable toxicity
  • For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Solid Tumors

  • 600 mg orally once a day until disease progression or unacceptable toxicity
  • For adult patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Pediatric Dose for Solid Tumors

12 years and older:

  • Body surface area (BSA) greater than 1.5 m2: 600 mg orally once a day
  • BSA 1.11 to 1.5 m2: 500 mg orally once a day
  • BSA 0.91 to 1.1 m2: 400 mg orally once a day

Renal Dose Adjustments

  • Mild or moderate renal impairment (CrCl 30 to less than 90 mL/min: No adjustment recommended.
  • Severe renal impairment (CrCl greater than 30 mL/min): Data not available

Liver Dose Adjustments

  • Grade 3 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
  • Grade 4 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at a reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.
  • ALT or AST greater than 3 times the upper limit of normal (ULN) with concurrent total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1.5 x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue therapy.

Dose Adjustments

DOSE REDUCTIONS FOR ADVERSE REACTIONS:
FIRST DOSE REDUCTION:

  • Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 400 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 400 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 300 mg orally once daily

SECOND DOSE REDUCTION (if the patient cannot tolerate the second dose reduction permanently discontinue therapy):

  • Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 200 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 200 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 200 mg orally once daily

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
CONGESTIVE HEART FAILURE:

  • Grade 2 or 3: Withhold therapy until recovered to less than or equal to Grade 1; resume at a reduced dose.
  • Grade 4: Permanently discontinue therapy.

CENTRAL NERVOUS SYSTEM EFFECTS:

  • Intolerable Grade 2: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose.
  • Grade 3: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if the adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
  • Grade 4: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue therapy for recurrent Grade 4 events.

HYPERURICEMIA:

  • QTc greater than 500 ms: Withhold therapy until QTc interval recovers to baseline; resume at the same dose if factors that cause QT prolongation are identified and corrected; resume at a reduced dose if other factors that cause QT prolongation are not identified.
  • Torsade de Pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia: Permanently discontinue therapy.

VISION DISORDERS:

  • Grade 2 or higher: Withhold therapy until improvement or stabilization; resume at the same dose or reduced dose as appropriate.

ANEMIA OR bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">NEUTROPENIA:

  • Grade 3 or 4: Withhold therapy until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline; resume at the same or reduced dose, if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.

DOSAGE MODIFICATIONS FOR DRUG INTERACTIONS: MODERATE AND STRONG CYP450 3A INHIBITORS:
Adults and pediatric patients 12 years and older with BSA Greater than 1.5 m2: Avoid coadministration of this drug with moderate or strong CYP450 3A inhibitors; if coadministration cannot be avoided, reduce the dose of this drug as follows:

  • Moderate CYP450 3A Inhibitors: 200 mg orally once daily
  • Strong CYP450 3A Inhibitors: 100 mg orally once daily

After discontinuation of a strong or moderate CYP450 3A inhibitor for 3 to 5 elimination half-lives, resume the dose that was taken prior to initiating the CYP450 3A inhibitor.

Administration advice:

  • This drug may be taken with or without food.
  • Swallow capsules whole do not open, crush, chew, or dissolve the contents of the capsule.
  • If a dose is missed, take it as soon as it is remembered unless the next dose is due within 12 hours.
  • If a patient vomits immediately after taking a dose, instruct them to repeat that dose.

Side Effects

The Most Common

  • tiredness
  • constipation
  • diarrhea
  • taste changes
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • cough, fever, or other signs of infection
  • muscle or joint pain
  • pain: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">back pain
  • weight changes
  • rash
  • difficulty falling or staying asleep
  • difficulty with learning, memory, attention, or problem solving
  • mood changes such as anxiety, depression, confusion, or agitation
  • bone pain or difficulty moving
  • vision problems or changes in vision
  • joint pain, stiffness, redness, or swelling
  • pain in upper right part of the stomach, yellowing of skin or eyes, loss of appetite, or bleeding or bruising easily
  • shortness of breath; difficulty breathing when lying down; or swelling of the arms, legs, hands, or feet

More common

  • Abdominal or stomach pain or tenderness
  • blurred vision
  • burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings
  • change in color vision
  • clay-colored stools
  • confusion
  • dark urine
  • decreased appetite
  • defects in intelligence, short-term memory, learning ability, and attention
  • difficulty seeing at night
  • dizziness
  • fever
  • headache
  • increased sensitivity of the eyes to sunlight
  • itching or skin rash
  • joint pain, stiffness, or swelling
  • loss of appetite
  • lower back, side, or stomach pain
  • nausea and vomiting
  • problems with balance
  • sleepiness or unusual drowsiness
  • swelling of the feet or lower legs
  • trouble sleeping
  • unusual tiredness or weakness
  • yellow eyes or skin

Rare

  • Chest pain
  • decreased urine output
  • dilated neck veins
  • double vision
  • extreme fatigue
  • fainting
  • irregular breathing
  • irregular heartbeat recurrent
  • loss of memory
  • problems with memory
  • problems with speech or speaking
  • seeing double
  • seeing, hearing, or feeling things that are not there
  • swelling of the face, fingers, feet, or lower legs
  • tightness in the chest
  • trouble remembering
  • troubled breathing
  • weight gain

Drug Interaction

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

This drug can harm a developing fetus. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Advise female patients of reproductive potential to use effective contraception during therapy and for at least 5 weeks after. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 3 months after.

Lactation

Use is not recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available
The effects in the nursing infant are unknown. Because of the potential for adverse reactions in breastfed infants from this drug, advise lactating women to discontinue breastfeeding during therapy and for 7 days after.

How should this medicine be used?

Entrectinib comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take entrectinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take entrectinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open, chew, or crush them.

If you vomit immediately after you take entrectinib, take another dose as soon as possible.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking entrectinib,

  • tell your doctor and pharmacist if you are allergic to entrectinib, any other medications, or any of the ingredients in entrectinib capsules. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the following: aprepitant (Emend), certain antifungal medications such as fluconazole (Diflucan), itraconazole (Omel, Sporanox), or ketoconazole; certain medications for arrhythmias such as amiodarone (Nexterone, Pacerone), procainamide, quinidine (in Nuedexta), and sotalol (Betapace, Sorine, Sotylize); azithromycin (Zithromax); clarithromycin (Biaxin, in Prevpac); diltiazem (Cardizem, Tiazac, others); erythromycin (E.E.S., Erythrocin, others); enzalutamide (Xtandi); certain HIV medications such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, others), or saquinavir (Invirase); lithium (Lithobid); modafinil (Provigil); nefazodone; oxcarbazepine (Trileptal); phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus, Duetact, Oseni); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifater); oral steroids such as dexamethasone, methylprednisolone (Medrol), and prednisone (Rayos); and verapamil (Calan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with entrectinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor what herbal products you are taking, especially St. John’s Wort.
  • tell your doctor if you have or have ever had a nervous system condition, a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), a slow or irregular heartbeat, a heart attack, heart failure, or heart or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for at least 5 weeks after your final dose. If you are a male, you and your partner should use birth control during your treatment with entrectinib and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking entrectinib, call your doctor immediately. Entrectinib may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking entrectinib and for 7 days after the final dose.
  • you should know that entrectinib may make cause dizziness or confusion. Do not drive a car or operate machinery until you know how this medication affects you.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Entrectinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Entrectinib is a tyrosine kinase inhibitor that acts on several receptors. It functions as an ATP competitor to inhibit tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC, as well as proto-oncogene tyrosine-protein kinase ROS1 and anaplastic lymphoma kinase (ALK). TRK receptors produce cell proliferation via downstream signaling through the mitogen-activated protein kinase, phosphoinositide 3-kinase, and phospholipase C-γ. ALK produces similar signaling with the addition of downstream JAK/STAT activation. Inhibition of these pathways suppresses cancer cell proliferation and shifts the balance in favor of apoptosis resulting in the shrinking of tumor volume. Indications Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available. Rozlytrek as monotherapy is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced nonsmall cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors. Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK) and ROS1 that is used to treat solid tumors with NTRK gene fusion and non-small cell lung cancer with ROS1 mutations. Metastatic Non-Small Cell Lung Cancer Solid Metastatic Tumor Solid Tumors In the US, entrectinib is indicated to treat patients whose cancers are ROS1-positive (have a specific genetic feature (biomarker)).[rx] It is to be used in those with solid tumors that:[rx] are caused by certain abnormal neurotrophic tyrosine receptor kinase (NTRK) genes, and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no acceptable treatment, or the cancer grew or spreads on other treatment Entrectinib is not approved for use in those less than twelve years of age. In the European Union, entrectinib as monotherapy is indicated for the treatment of adults and adolescents twelve years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,[rx] who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and[rx] who have not received a prior NTRK inhibitor[rx] who have no satisfactory treatment options?[rx] It is also indicated for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.[rx] Use in Cancer Entrectinib is approved to treat: Non-small cell lung cancer that is ROS1 positive. It is used in adults whose cancer has metastasized (spread to other parts of the body). Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins. It is used in adults and in children aged 12 years or older whose cancer has metastasized or cannot be removed by surgery and has gotten worse after other treatments or cannot be treated with other therapies.¹ ¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that entrectinib provides a clinical benefit in these patients. Entrectinib is also being studied in the treatment of other types of cancer. Contraindications low amount of magnesium in the blood low amount of calcium in the blood low amount of potassium in the blood chronic heart failure abnormal EKG with QT changes from birth liver problems high amount of uric acid in the blood pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 100 mg; 200 mg Non-Small Cell Lung Cancer 600 mg orally once a day until disease progression or unacceptable toxicity For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive Solid Tumors 600 mg orally once a day until disease progression or unacceptable toxicity For adult patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Pediatric Dose for Solid Tumors 12 years and older: Body surface area (BSA) greater than 1.5 m2: 600 mg orally once a day BSA 1.11 to 1.5 m2: 500 mg orally once a day BSA 0.91 to 1.1 m2: 400 mg orally once a day Renal Dose Adjustments Mild or moderate renal impairment (CrCl 30 to less than 90 mL/min: No adjustment recommended. Severe renal impairment (CrCl greater than 30 mL/min): Data not available Liver Dose Adjustments Grade 3 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks. Grade 4 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at a reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events. ALT or AST greater than 3 times the upper limit of normal (ULN) with concurrent total bilirubin greater than 1.5 x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue therapy. Dose Adjustments DOSE REDUCTIONS FOR ADVERSE REACTIONS: FIRST DOSE REDUCTION: Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 400 mg orally once daily Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 400 mg orally once daily Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 300 mg orally once daily SECOND DOSE REDUCTION (if the patient cannot tolerate the second dose reduction permanently discontinue therapy): Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 200 mg orally once daily Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 200 mg orally once daily Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 200 mg orally once daily DOSE MODIFICATIONS FOR ADVERSE REACTIONS: CONGESTIVE HEART FAILURE: Grade 2 or 3: Withhold therapy until recovered to less than or equal to Grade 1; resume at a reduced dose. Grade 4: Permanently discontinue therapy. CENTRAL NERVOUS SYSTEM EFFECTS: Intolerable Grade 2: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose. Grade 3: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if the adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks. Grade 4: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue therapy for recurrent Grade 4 events. HYPERURICEMIA: QTc greater than 500 ms: Withhold therapy until QTc interval recovers to baseline; resume at the same dose if factors that cause QT prolongation are identified and corrected; resume at a reduced dose if other factors that cause QT prolongation are not identified. Torsade de Pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia: Permanently discontinue therapy. VISION DISORDERS: Grade 2 or higher: Withhold therapy until improvement or stabilization; resume at the same dose or reduced dose as appropriate. ANEMIA OR NEUTROPENIA: Grade 3 or 4: Withhold therapy until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline; resume at the same or reduced dose, if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events. DOSAGE MODIFICATIONS FOR DRUG INTERACTIONS: MODERATE AND STRONG CYP450 3A INHIBITORS: Adults and pediatric patients 12 years and older with BSA Greater than 1.5 m2: Avoid coadministration of this drug with moderate or strong CYP450 3A inhibitors; if coadministration cannot be avoided, reduce the dose of this drug as follows: Moderate CYP450 3A Inhibitors: 200 mg orally once daily Strong CYP450 3A Inhibitors: 100 mg orally once daily After discontinuation of a strong or moderate CYP450 3A inhibitor for 3 to 5 elimination half-lives, resume the dose that was taken prior to initiating the CYP450 3A inhibitor. Administration advice: This drug may be taken with or without food. Swallow capsules whole do not open, crush, chew, or dissolve the contents of the capsule. If a dose is missed, take it as soon as it is remembered unless the next dose is due within 12 hours. If a patient vomits immediately after taking a dose, instruct them to repeat that dose. Side Effects The Most Common tiredness constipation diarrhea taste changes headache cough, fever, or other signs of infection muscle or joint pain back pain weight changes rash difficulty falling or staying asleep difficulty with learning, memory, attention, or problem solving mood changes such as anxiety, depression, confusion, or agitation bone pain or difficulty moving vision problems or changes in vision joint pain, stiffness, redness, or swelling pain in upper right part of the stomach, yellowing of skin or eyes, loss of appetite, or bleeding or bruising easily shortness of breath; difficulty breathing when lying down; or swelling of the arms, legs, hands, or feet More common Abdominal or stomach pain or tenderness blurred vision burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings change in color vision clay-colored stools confusion dark urine decreased appetite defects in intelligence, short-term memory, learning ability, and attention difficulty seeing at night dizziness fever headache increased sensitivity of the eyes to sunlight itching or skin rash joint pain, stiffness, or swelling loss of appetite lower back, side, or stomach pain nausea and vomiting problems with balance sleepiness or unusual drowsiness swelling of the feet or lower legs trouble sleeping unusual tiredness or weakness yellow eyes or skin Rare Chest pain decreased urine output dilated neck veins double vision extreme fatigue fainting irregular breathing irregular heartbeat recurrent loss of memory problems with memory problems with speech or speaking seeing double seeing, hearing, or feeling things that are not there swelling of the face, fingers, feet, or lower legs tightness in the chest trouble remembering troubled breathing weight gain Drug Interaction DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Entrectinib. Abametapir The serum concentration of Entrectinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Entrectinib can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Entrectinib. Acalabrutinib The metabolism of Entrectinib can be decreased when combined with Acalabrutinib. Acebutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Entrectinib. Acetaminophen The metabolism of Entrectinib can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Entrectinib can be decreased when combined with Acetazolamide. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Entrectinib. Adalimumab The metabolism of Entrectinib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Entrectinib. Afatinib The serum concentration of Afatinib can be increased when it is combined with Entrectinib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Entrectinib. Albendazole The metabolism of Entrectinib can be decreased when combined with Albendazole. Aldesleukin The metabolism of Entrectinib can be decreased when combined with Aldesleukin. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Entrectinib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Entrectinib. Alpelisib The metabolism of Entrectinib can be increased when combined with Alpelisib. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Entrectinib. Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Entrectinib. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Entrectinib. Aminoglutethimide The metabolism of Entrectinib can be increased when combined with Aminoglutethimide. Amiodarone The metabolism of Entrectinib can be decreased when combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Entrectinib. Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Entrectinib. Amlodipine The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Entrectinib. Amobarbital The metabolism of Entrectinib can be increased when combined with Amobarbital. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Entrectinib. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Entrectinib. Amprenavir The metabolism of Entrectinib can be increased when combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Entrectinib. Anakinra The metabolism of Entrectinib can be increased when combined with Anakinra. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Entrectinib. Apalutamide The metabolism of Entrectinib can be increased when combined with Apalutamide. Apixaban The serum concentration of Apixaban can be increased when it is combined with Entrectinib. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Entrectinib. Apremilast The metabolism of Entrectinib can be increased when combined with Apremilast. Aprepitant The metabolism of Entrectinib can be decreased when combined with Aprepitant. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Entrectinib. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Entrectinib. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Entrectinib. Armodafinil The metabolism of Entrectinib can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Entrectinib. Artemether The risk or severity of QTc prolongation can be increased when Artemether is combined with Entrectinib. Articaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Articaine. Asciminib The serum concentration of Entrectinib can be increased when it is combined with Asciminib. Asenapine The risk or severity of QTc prolongation can be increased when Asenapine is combined with Entrectinib. Astemizole The risk or severity of QTc prolongation can be increased when Astemizole is combined with Entrectinib. Asunaprevir The metabolism of Entrectinib can be increased when combined with Asunaprevir. Atazanavir The metabolism of Entrectinib can be decreased when combined with Atazanavir. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Entrectinib. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Entrectinib. Avacopan The metabolism of Entrectinib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Entrectinib. Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Entrectinib. Axitinib The serum concentration of Axitinib can be increased when it is combined with Entrectinib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Entrectinib. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Entrectinib. Beclomethasone The metabolism of Entrectinib can be increased when combined with Beclomethasone dipropionate. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Entrectinib. Belantamab The serum concentration of Belantamab mafodotin can be increased when it is combined with Entrectinib. Belinostat The serum concentration of Belinostat can be increased when it is combined with Entrectinib. Belzutifan The serum concentration of Entrectinib can be decreased when it is combined with Belzutifan. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Entrectinib. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Entrectinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Bepridil is combined with Entrectinib. Berotralstat The metabolism of Entrectinib can be decreased when combined with Berotralstat. Betamethasone The metabolism of Entrectinib can be increased when combined with Betamethasone. Betamethasone The metabolism of Entrectinib can be increased when combined with Betamethasone phosphate. Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Entrectinib. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Entrectinib. Bexarotene The metabolism of Entrectinib can be increased when combined with Bexarotene. Bicalutamide The metabolism of Entrectinib can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Entrectinib can be decreased when combined with Bifonazole. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Entrectinib. Bimekizumab The metabolism of Entrectinib can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Entrectinib. Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Entrectinib. Boceprevir The metabolism of Entrectinib can be decreased when combined with Boceprevir. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Entrectinib. Bosentan The metabolism of Entrectinib can be increased when combined with Bosentan. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Entrectinib. Brentuximab The serum concentration of Brentuximab vedotin can be increased when it is combined with Entrectinib. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Entrectinib. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Entrectinib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Entrectinib. Budesonide The metabolism of Entrectinib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Bupivacaine. Buprenorphine The metabolism of Entrectinib can be decreased when combined with Buprenorphine. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Entrectinib. Butacaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Butacaine. Butalbital The metabolism of Entrectinib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Entrectinib. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Entrectinib. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Entrectinib. Calcitriol The metabolism of Entrectinib can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib. Canakinumab The metabolism of Entrectinib can be increased when combined with Canakinumab. Candicidin The metabolism of Entrectinib can be decreased when combined with Candicidin. Cannabidiol The metabolism of Entrectinib can be decreased when combined with Cannabidiol. Capsaicin The metabolism of Entrectinib can be decreased when combined with Capsaicin. Carbamazepine The metabolism of Entrectinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Entrectinib. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Entrectinib. Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Entrectinib. Cefradine The metabolism of Entrectinib can be increased when combined with Cefradine. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Entrectinib. Cenobamate The metabolism of Entrectinib can be increased when combined with Cenobamate. Cephalexin The metabolism of Entrectinib can be decreased when combined with Cephalexin. Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Entrectinib. Cerivastatin The metabolism of Entrectinib can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Entrectinib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Entrectinib. Chloramphenicol The metabolism of Entrectinib can be decreased when combined with Chloramphenicol. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Entrectinib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Entrectinib. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Entrectinib. Chlorpromazine The metabolism of Entrectinib can be increased when combined with Chlorpromazine. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Entrectinib. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Entrectinib. Cimetidine The metabolism of Entrectinib can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Entrectinib. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Entrectinib. Ciprofloxacin The metabolism of Entrectinib can be decreased when combined with Ciprofloxacin. Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Entrectinib. Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Entrectinib. Clarithromycin The metabolism of Entrectinib can be decreased when combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Entrectinib. Clevidipine The metabolism of Entrectinib can be increased when combined with Clevidipine. Clobazam The metabolism of Entrectinib can be increased when combined with Clobazam. Clobetasol The metabolism of Entrectinib can be increased when combined with Clobetasol propionate. Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Entrectinib. Clofibrate The metabolism of Entrectinib can be increased when combined with Clofibrate. Clomifene The serum concentration of Clomifene can be increased when it is combined with Entrectinib. Clomipramine The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Entrectinib. Clozapine The metabolism of Entrectinib can be increased when combined with Clozapine. Cobicistat The metabolism of Entrectinib can be decreased when combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Entrectinib. Cocaine The risk or severity of QTc prolongation can be increased when Cocaine is combined with Entrectinib. Colchicine The serum concentration of Colchicine can be increased when it is combined with Entrectinib. Conivaptan The metabolism of Entrectinib can be decreased when combined with Conivaptan. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Entrectinib. Corticotropin The metabolism of Entrectinib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Entrectinib can be increased when combined with Cortisone acetate. Crizotinib The metabolism of Entrectinib can be decreased when combined with Crizotinib. Curcumin The metabolism of Entrectinib can be decreased when combined with Curcumin. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Entrectinib. Cyclophosphamide The metabolism of Entrectinib can be increased when combined with Cyclophosphamide. Cyclosporine The metabolism of Entrectinib can be decreased when combined with Cyclosporine. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Entrectinib. Cyproterone acetate The metabolism of Entrectinib can be decreased when combined with Cyproterone acetate. Dabigatran etexilate The serum concentration of Dabigatran etexilate can be increased when it is combined with Entrectinib. Dabrafenib The metabolism of Entrectinib can be increased when combined with Dabrafenib. Dacomitinib The serum concentration of Dacomitinib can be increased when it is combined with Entrectinib. Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Entrectinib. Dalfopristin The metabolism of Entrectinib can be decreased when combined with Dalfopristin. Danazol The metabolism of Entrectinib can be decreased when combined with Danazol. Daptomycin The serum concentration of Daptomycin can be increased when it is combined with Entrectinib. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Entrectinib. Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Entrectinib. Darunavir The metabolism of Entrectinib can be decreased when combined with Darunavir. Dasabuvir The serum concentration of Dasabuvir can be increased when it is combined with Entrectinib. Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Entrectinib. Daunorubicin The metabolism of Entrectinib can be decreased when combined with Daunorubicin. Deferasirox The metabolism of Entrectinib can be increased when combined with Deferasirox. Deflazacort The metabolism of Entrectinib can be increased when combined with Deflazacort. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Entrectinib. Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Entrectinib. Delamanid The risk or severity of QTc prolongation can be increased when Delamanid is combined with Entrectinib. Delavirdine The metabolism of Entrectinib can be decreased when combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Entrectinib. Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Entrectinib. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Entrectinib. Desvenlafaxine The metabolism of Entrectinib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Entrectinib. Dexamethasone The metabolism of Entrectinib can be increased when combined with Dexamethasone. Dexamethasone The metabolism of Entrectinib can be increased when combined with Dexamethasone acetate. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Entrectinib. Dexchlorphenir The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Entrectinib. Dextropropoxyphene The metabolism of Entrectinib can be decreased when combined with Dextropropoxyphene. Dicloxacillin The metabolism of Entrectinib can be increased when combined with Dicloxacillin. Diethylstilbestrol The metabolism of Entrectinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Entrectinib can be increased when combined with Difluocortolone. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Entrectinib. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Entrectinib. Dihydroergocornine The metabolism of Entrectinib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Entrectinib can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Entrectinib can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Entrectinib can be decreased when combined with Diltiazem. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Entrectinib. Dimethyl sulfoxide The metabolism of Entrectinib can be decreased when combined with Dimethyl sulfoxide. Diosmin The metabolism of Entrectinib can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Entrectinib. Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Entrectinib. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Entrectinib. Docetaxel The metabolism of Entrectinib can be decreased when combined with Docetaxel. Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Entrectinib. Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Entrectinib. Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Entrectinib. Domperidone The risk or severity of QTc prolongation can be increased when Domperidone is combined with Entrectinib. Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Entrectinib. Doxazosin The metabolism of Entrectinib can be decreased when combined with Doxazosin. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Entrectinib. Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Entrectinib. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Entrectinib. Dronedarone The metabolism of Entrectinib can be decreased when combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Entrectinib. Drospirenone The metabolism of Entrectinib can be decreased when combined with Drospirenone. Duvelisib The metabolism of Entrectinib can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Dyclonine. Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Entrectinib. Echinacea The metabolism of Entrectinib can be increased when combined with Echinacea. Econazole The metabolism of Entrectinib can be decreased when combined with Econazole. Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Entrectinib. Efavirenz The metabolism of Entrectinib can be increased when combined with Efavirenz. Elagolix The serum concentration of Elagolix can be increased when it is combined with Entrectinib. Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Entrectinib. Elexacaftor The metabolism of Entrectinib can be decreased when combined with Elexacaftor. Eliglustat The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Entrectinib. Elvitegravir The metabolism of Entrectinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Entrectinib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Entrectinib. Enasidenib The metabolism of Entrectinib can be increased when combined with Enasidenib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Entrectinib. Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Entrectinib. Enfortumab The serum concentration of Enfortumab vedotin can be increased when it is combined with Entrectinib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Entrectinib. Enzalutamide The metabolism of Entrectinib can be increased when combined with Enzalutamide. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Entrectinib. Epinephrine The metabolism of Entrectinib can be decreased when combined with Epinephrine. Ergotamine The metabolism of Entrectinib can be decreased when combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Entrectinib. Erlotinib The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Entrectinib. Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Entrectinib. Erythromycin The metabolism of Entrectinib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Entrectinib. Escitalopram The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Entrectinib. Esketamine The metabolism of Entrectinib can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Entrectinib can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Entrectinib can be increased when combined with Eslicarbazepine acetate. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Entrectinib. Estetrol The metabolism of Entrectinib can be decreased when combined with Estetrol. Estradiol acetate The metabolism of Entrectinib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Entrectinib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Entrectinib can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Entrectinib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Entrectinib can be increased when combined with Estradiol valerate. Etanercept The metabolism of Entrectinib can be increased when combined with Etanercept. Ethambutol The metabolism of Entrectinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Entrectinib can be increased when combined with Ethanol. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Entrectinib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Etidocaine. Etoposide The serum concentration of Etoposide can be increased when it is combined with Entrectinib. Etoricoxib The metabolism of Entrectinib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Entrectinib can be increased when combined with Etravirine. Everolimus The serum concentration of Everolimus can be increased when it is combined with Entrectinib. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Entrectinib. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Entrectinib. Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Entrectinib. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Entrectinib. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Entrectinib. Fenofibrate The metabolism of Entrectinib can be decreased when combined with Fenofibrate. Fexinidazole The risk or severity of adverse effects can be increased when Entrectinib is combined with Fexinidazole. Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Entrectinib. Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Entrectinib. Flucloxacillin The metabolism of Entrectinib can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Entrectinib can be decreased when combined with Fluconazole. Flunisolide The metabolism of Entrectinib can be increased when combined with Flunisolide. Fluocinolone The metabolism of Entrectinib can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Entrectinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Entrectinib can be increased when combined with Fluocortolone. Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Entrectinib. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Entrectinib. Flupentixol The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Entrectinib. Fluspirilene The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Entrectinib. Fluticasone The metabolism of Entrectinib can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Entrectinib can be increased when combined with Fluticasone furoate. Fluticasone The metabolism of Entrectinib can be decreased when combined with Fluticasone propionate. Fluvoxamine The metabolism of Entrectinib can be decreased when combined with Fluvoxamine. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib. Formestane The metabolism of Entrectinib can be increased when combined with Formestane. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Entrectinib. Fosamprenavir The metabolism of Entrectinib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Entrectinib can be increased when combined with Fosaprepitant. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Entrectinib. Fosnetupitant The metabolism of Entrectinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Entrectinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Entrectinib can be decreased when combined with Fostamatinib. Fostemsavir The serum concentration of Fostemsavir can be increased when it is combined with Entrectinib. Fusidic acid The metabolism of Entrectinib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Entrectinib. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Entrectinib. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Entrectinib. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Entrectinib. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Entrectinib. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Entrectinib. Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Entrectinib. Ginkgo biloba The metabolism of Entrectinib can be decreased when combined with Ginkgo biloba. Glasdegib The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Entrectinib. Glecaprevir The metabolism of Entrectinib can be decreased when combined with Glecaprevir. Glyburide The metabolism of Entrectinib can be decreased when combined with Glyburide. Glycerol The metabolism of Entrectinib can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Entrectinib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entrectinib. Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Entrectinib. Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Entrectinib. Grepafloxacin The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Entrectinib. Griseofulvin The metabolism of Entrectinib can be increased when combined with Griseofulvin. Halofantrine The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Entrectinib. Haloperidol The metabolism of Entrectinib can be decreased when combined with Haloperidol. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Entrectinib. Hydralazine The metabolism of Entrectinib can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Entrectinib. Hydrocortamate The metabolism of Entrectinib can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Entrectinib can be increased when combined with Hydrocortisone. Hydrocortisone The metabolism of Entrectinib can be increased when combined with Hydrocortisone acetate. Hydrocortisone The metabolism of Entrectinib can be increased when combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Entrectinib can be increased when combined with Hydrocortisone succinate. Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Entrectinib. Hydroxyzine The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Entrectinib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entrectinib. Ibutilide The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Entrectinib. Idelalisib The metabolism of Entrectinib can be decreased when combined with Idelalisib. Ifosfamide The metabolism of Entrectinib can be increased when combined with Ifosfamide. Iloperidone The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Entrectinib. Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Entrectinib. Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Entrectinib. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Entrectinib. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Entrectinib. Indinavir The metabolism of Entrectinib can be decreased when combined with Indinavir. Infigratinib The metabolism of Entrectinib can be decreased when combined with Infigratinib. Infliximab The metabolism of Entrectinib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Entrectinib. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Entrectinib. Irbesartan The metabolism of Entrectinib can be decreased when combined with Irbesartan. Isavuconazole The metabolism of Entrectinib can be decreased when combined with Isavuconazole. Isavuconazonium The metabolism of Entrectinib can be increased when combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Entrectinib. Isoniazid The metabolism of Entrectinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Entrectinib can be decreased when combined with Isradipine. Itraconazole The metabolism of Entrectinib can be decreased when combined with Itraconazole. Ivabradine The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Entrectinib. Ivacaftor The metabolism of Entrectinib can be decreased when combined with Ivacaftor. Ivosidenib The metabolism of Entrectinib can be increased when combined with Ivosidenib. Ketazolam The metabolism of Entrectinib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Entrectinib can be decreased when combined with Ketoconazole. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Entrectinib. Lacosamide The metabolism of Entrectinib can be decreased when combined with Lacosamide. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Entrectinib. Lanreotide The metabolism of Entrectinib can be decreased when combined with Lanreotide. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Entrectinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Entrectinib. Lasmiditan The serum concentration of Lasmiditan can be increased when it is combined with Entrectinib. Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Entrectinib. Lefamulin Lefamulin may increase the QTc-prolonging activities of Entrectinib. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Entrectinib. Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Entrectinib. Lesinurad The metabolism of Entrectinib can be increased when combined with Lesinurad. Letermovir The metabolism of Entrectinib can be decreased when combined with Letermovir. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entrectinib. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Entrectinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Entrectinib. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Entrectinib. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Entrectinib. Levoketoconazole The metabolism of Entrectinib can be decreased when combined with Levoketoconazole. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Entrectinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Entrectinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Entrectinib. Linagliptin The metabolism of Entrectinib can be decreased when combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Entrectinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Entrectinib. Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Entrectinib. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Entrectinib. Lomitapide The metabolism of Entrectinib can be decreased when combined with Lomitapide. Lonafarnib The metabolism of Entrectinib can be decreased when combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Entrectinib. Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Entrectinib. Lopinavir The metabolism of Entrectinib can be decreased when combined with Lopinavir. Lorlatinib The metabolism of Entrectinib can be increased when combined with Lorlatinib. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Entrectinib. Lovastatin The metabolism of Entrectinib can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Entrectinib can be increased when combined with Lumacaftor. Lumefantrine The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Entrectinib. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Entrectinib. Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Entrectinib. Macimorelin The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Entrectinib. Manidipine The metabolism of Entrectinib can be decreased when combined with Manidipine. Mannitol The serum concentration of Mannitol can be increased when it is combined with Entrectinib. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Entrectinib. Mavacamten The metabolism of Entrectinib can be increased when combined with Mavacamten. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Entrectinib. Meloxicam The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Meloxicam. Meperidine The metabolism of Entrectinib can be decreased when combined with Meperidine. Mepivacaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Mepivacaine. Meprednisone The metabolism of Entrectinib can be increased when combined with Meprednisone. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Entrectinib. Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Entrectinib. Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Entrectinib. Methimazole The metabolism of Entrectinib can be decreased when combined with Methimazole. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Entrectinib. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Entrectinib. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Entrectinib. Methylene blue The metabolism of Entrectinib can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Entrectinib can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Entrectinib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Entrectinib can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Entrectinib can be decreased when combined with Methylprednisone. Methysergide The metabolism of Entrectinib can be decreased when combined with Methysergide. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Entrectinib. Metreleptin The metabolism of Entrectinib can be increased when combined with Metreleptin. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Entrectinib. Metyrapone The metabolism of Entrectinib can be increased when combined with Metyrapone. Miconazole The metabolism of Entrectinib can be decreased when combined with Miconazole. Midazolam The metabolism of Entrectinib can be decreased when combined with Midazolam. Midostaurin The metabolism of Entrectinib can be increased when combined with Midostaurin. Mifepristone The metabolism of Entrectinib can be increased when combined with Mifepristone. Milnacipran The metabolism of Entrectinib can be decreased when combined with Milnacipran. Miocamycin The metabolism of Entrectinib can be decreased when combined with Miocamycin. Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Entrectinib. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Entrectinib. Mitapivat The metabolism of Entrectinib can be increased when combined with Mitapivat. Mitotane The metabolism of Entrectinib can be increased when combined with Mitotane. Mizolastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Entrectinib. Mobocertinib The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Mobocertinib. Modafinil The metabolism of Entrectinib can be increased when combined with Modafinil. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Entrectinib. Mometasone The metabolism of Entrectinib can be increased when combined with Mometasone furoate. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Entrectinib. Morphine The serum concentration of Morphine can be increased when it is combined with Entrectinib. Mosunetuzumab The metabolism of Entrectinib can be decreased when combined with Mosunetuzumab. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entrectinib. Nafcillin The metabolism of Entrectinib can be increased when combined with Nafcillin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Entrectinib. Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Entrectinib. Naloxone The metabolism of Entrectinib can be decreased when combined with Naloxone. Nefazodone The metabolism of Entrectinib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Entrectinib can be decreased when combined with Nelfinavir. Netupitant The metabolism of Entrectinib can be decreased when combined with Netupitant. Niacin The metabolism of Entrectinib can be decreased when combined with Niacin. Nicardipine The metabolism of Entrectinib can be decreased when combined with Nicardipine. Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Entrectinib. Nilotinib The metabolism of Entrectinib can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Entrectinib can be decreased when combined with Nilvadipine. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Entrectinib. Nintedanib The metabolism of Entrectinib can be decreased when combined with Nintedanib. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Entrectinib. Norethisterone The metabolism of Entrectinib can be decreased when combined with Norethisterone. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Entrectinib. Norgestimate The metabolism of Entrectinib can be increased when combined with Norgestimate. Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Entrectinib. Noscapine The metabolism of Entrectinib can be decreased when combined with Noscapine. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entrectinib. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Entrectinib. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Entrectinib. Olaparib The metabolism of Entrectinib can be decreased when combined with Olaparib. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Entrectinib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Entrectinib. Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Entrectinib. Omeprazole The metabolism of Entrectinib can be increased when combined with Omeprazole. Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Entrectinib. Oritavancin The metabolism of Entrectinib can be increased when combined with Oritavancin. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Entrectinib. Osilodrostat The metabolism of Entrectinib can be decreased when combined with Osilodrostat. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Entrectinib. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Entrectinib. Oxatomide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Entrectinib. Oxcarbazepine The metabolism of Entrectinib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Oxetacaine. Oxprenolol The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Entrectinib. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Entrectinib can be decreased when combined with Oxybutynin. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entrectinib. Paclitaxel The metabolism of Entrectinib can be increased when combined with Paclitaxel. Pacritinib The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Entrectinib. Palbociclib The metabolism of Entrectinib can be decreased when combined with Palbociclib. Paliperidone The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Entrectinib. Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Entrectinib. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Entrectinib. Parathyroid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Entrectinib. Paritaprevir The serum concentration of Paritaprevir can be increased when it is combined with Entrectinib. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Entrectinib. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Entrectinib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Entrectinib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Entrectinib. Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Entrectinib. Pentobarbital The metabolism of Entrectinib can be increased when combined with Pentobarbital. Perampanel The metabolism of Entrectinib can be increased when combined with Perampanel. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Entrectinib. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Entrectinib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Entrectinib. Phenobarbital The metabolism of Entrectinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Phenol. Phenylbutazone The metabolism of Entrectinib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Entrectinib can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Entrectinib. Pimavanserin The metabolism of Entrectinib can be decreased when combined with Pimavanserin. Pimozide The risk or severity of QTc prolongation can be increased when Pimozide is combined with Entrectinib. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Entrectinib. Piperaquine The metabolism of Entrectinib can be decreased when combined with Piperaquine. Pitolisant The metabolism of Entrectinib can be increased when combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Entrectinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Entrectinib. Posaconazole The metabolism of Entrectinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Entrectinib. Potassium The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Entrectinib. Pralsetinib The metabolism of Entrectinib can be increased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Pramocaine. Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Entrectinib. Prednisolone The metabolism of Entrectinib can be increased when combined with Prednisolone. Prednisolone acet The metabolism of Entrectinib can be increased when combined with Prednisolone acetate. Prednisolone The metabolism of Entrectinib can be increased when combined with Prednisolone phosphate. Prednisone The metabolism of Entrectinib can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Entrectinib. Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Entrectinib. Pretomanid The metabolism of Entrectinib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Prilocaine. Primaquine The metabolism of Entrectinib can be decreased when combined with Primaquine. Primidone The metabolism of Entrectinib can be increased when combined with Primidone. Probenecid The metabolism of Entrectinib can be increased when combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Entrectinib. Procainamide The risk or severity of QTc prolongation can be increased when Procainamide is combined with Entrectinib. Procaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Procaine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Entrectinib. Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Entrectinib. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Entrectinib. Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Entrectinib. Proparacaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Proparacaine. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Entrectinib. Propoxycaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Propoxycaine. Propranolol The risk or severity of QTc prolongation can be increased when Propranolol is combined with Entrectinib. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Entrectinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Entrectinib. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Entrectinib. Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Entrectinib. Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Entrectinib. Quinidine The risk or severity of QTc prolongation can be increased when Quinidine is combined with Entrectinib. Quinine The metabolism of Entrectinib can be increased when combined with Quinine. Quinupristin The metabolism of Entrectinib can be decreased when combined with Quinupristin. Raloxifene The metabolism of Entrectinib can be decreased when combined with Raloxifene. Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Entrectinib. Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Entrectinib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Entrectinib. Remdesivir The metabolism of Entrectinib can be decreased when combined with Remdesivir. Revefenacin The serum concentration of Revefenacin can be increased when it is combined with Entrectinib. Ribociclib The metabolism of Entrectinib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Entrectinib can be increased when combined with Rifabutin. Rifampicin The metabolism of Entrectinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Entrectinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Entrectinib can be increased when combined with Rifapentine. Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Entrectinib. Rilonacept The metabolism of Entrectinib can be increased when combined with Rilonacept. Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Entrectinib. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Entrectinib. Riociguat The serum concentration of Riociguat can be increased when it is combined with Entrectinib. Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Entrectinib. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Entrectinib. Ritonavir The metabolism of Entrectinib can be decreased when combined with Ritonavir. Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Entrectinib. Rofecoxib The metabolism of Entrectinib can be increased when combined with Rofecoxib. Roflumilast The metabolism of Entrectinib can be decreased when combined with Roflumilast. Romidepsin The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Entrectinib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Ropivacaine. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Entrectinib. Rosuvastatin The metabolism of Entrectinib can be decreased when combined with Rosuvastatin. Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Entrectinib. Rucaparib The metabolism of Entrectinib can be decreased when combined with Rucaparib. Rufinamide The metabolism of Entrectinib can be increased when combined with Rufinamide. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Entrectinib. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Entrectinib. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Entrectinib. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Entrectinib. Saquinavir The metabolism of Entrectinib can be decreased when combined with Saquinavir. Sarilumab The metabolism of Entrectinib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Entrectinib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Entrectinib can be increased when combined with Secobarbital. Secukinumab The metabolism of Entrectinib can be increased when combined with Secukinumab. Selexipag The serum concentration of Selexipag can be increased when it is combined with Entrectinib. Selpercatinib The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Entrectinib. Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Entrectinib. Sertindole The risk or severity of QTc prolongation can be increased when Sertindole is combined with Entrectinib. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Entrectinib. Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Entrectinib. Silodosin The excretion of Silodosin can be decreased when combined with Entrectinib. Siltuximab The metabolism of Entrectinib can be increased when combined with Siltuximab. Simeprevir The metabolism of Entrectinib can be decreased when combined with Simeprevir. Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Entrectinib. Siponimod The metabolism of Entrectinib can be decreased when combined with Siponimod. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Entrectinib. Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Entrectinib. Sitaxentan The metabolism of Entrectinib can be decreased when combined with Sitaxentan. Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Entrectinib. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Entrectinib. Somatostatin The metabolism of Entrectinib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Entrectinib can be increased when combined with Somatrogon. Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Entrectinib. Sotalol The risk or severity of QTc prolongation can be increased when Sotalol is combined with Entrectinib. Sotorasib The serum concentration of Entrectinib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Entrectinib. St. John's Wort The metabolism of Entrectinib can be increased when combined with St. John's Wort. Stiripentol The metabolism of Entrectinib can be increased when combined with Stiripentol. Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Entrectinib. Sulfinpyrazone The metabolism of Entrectinib can be increased when combined with Sulfinpyrazone. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Entrectinib. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Entrectinib. Sultopride The risk or severity of QTc prolongation can be increased when Sultopride is combined with Entrectinib. Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Entrectinib. Suvorexant The metabolism of Entrectinib can be decreased when combined with Suvorexant. Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Entrectinib. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Entrectinib. Tamoxifen The metabolism of Entrectinib can be increased when combined with Tamoxifen. Tasimelteon The metabolism of Entrectinib can be decreased when combined with Tasimelteon. Tazemetostat The metabolism of Entrectinib can be decreased when combined with Tazemetostat. Technetium The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Entrectinib. Tecovirimat The metabolism of Entrectinib can be increased when combined with Tecovirimat. Tegaserod The serum concentration of Tegaserod can be increased when it is combined with Entrectinib. Telaprevir The metabolism of Entrectinib can be decreased when combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Entrectinib. Telithromycin The metabolism of Entrectinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Entrectinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Entrectinib. Teniposide The metabolism of Entrectinib can be decreased when combined with Teniposide. Tenofovir The serum concentration of Tenofovir alafenamide can be increased when it is combined with Entrectinib. Tenofovir disoproxil The serum concentration of Tenofovir disoproxil can be increased when it is combined with Entrectinib. Tepotinib The serum concentration of Tepotinib can be increased when it is combined with Entrectinib. Terbinafine The metabolism of Entrectinib can be increased when combined with Terbinafine. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Entrectinib. Terfenadine The metabolism of Entrectinib can be decreased when combined with Terfenadine. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Entrectinib. Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Entrectinib. Testosterone The metabolism of Entrectinib can be increased when combined with Testosterone. Tetrabenazine The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Entrectinib. Tetracaine The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Tetracaine. Tetracycline The metabolism of Entrectinib can be decreased when combined with Tetracycline. Tezacaftor The serum concentration of Tezacaftor can be increased when it is combined with Entrectinib. Thiamylal The metabolism of Entrectinib can be increased when combined with Thiamylal. Thioridazine The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Entrectinib. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Entrectinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Entrectinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Entrectinib. Ticagrelor The metabolism of Entrectinib can be decreased when combined with Ticagrelor. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Entrectinib. Tioconazole The metabolism of Entrectinib can be decreased when combined with Tioconazole. Tipranavir The metabolism of Entrectinib can be decreased when combined with Tipranavir. Tivozanib The serum concentration of Tivozanib can be increased when it is combined with Entrectinib. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Entrectinib. Tocilizumab The metabolism of Entrectinib can be increased when combined with Tocilizumab. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Entrectinib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Entrectinib. Topiramate The metabolism of Entrectinib can be increased when combined with Topiramate. Topotecan The serum concentration of Topotecan can be increased when it is combined with Entrectinib. Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Entrectinib. Trastuzumab The serum concentration of Trastuzumab emtansine can be increased when it is combined with Entrectinib. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Entrectinib. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Entrectinib. Triamcinolone The metabolism of Entrectinib can be increased when combined with Triamcinolone. Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Entrectinib. Trilaciclib The serum concentration of Trilaciclib can be increased when it is combined with Entrectinib. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Entrectinib. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Entrectinib. Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Entrectinib. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Entrectinib. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Entrectinib. Troglitazone The metabolism of Entrectinib can be increased when combined with Troglitazone. Troleandomycin The metabolism of Entrectinib can be decreased when combined with Troleandomycin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Entrectinib. Tucatinib The metabolism of Tucatinib can be decreased when combined with Entrectinib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Entrectinib. Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Entrectinib. Valproic acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Entrectinib. Vandetanib The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Entrectinib. Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Entrectinib. Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Entrectinib. Vemurafenib The metabolism of Entrectinib can be increased when combined with Vemurafenib. Venetoclax The metabolism of Entrectinib can be decreased when combined with Venetoclax. Verapamil The metabolism of Entrectinib can be decreased when combined with Verapamil. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Entrectinib. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Entrectinib. Viloxazine The metabolism of Entrectinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Entrectinib can be increased when combined with Vinblastine. Vincristine The excretion of Vincristine can be decreased when combined with Entrectinib. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Entrectinib. Vitamin E The metabolism of Entrectinib can be increased when combined with Vitamin E. Voclosporin The serum concentration of Voclosporin can be increased when it is combined with Entrectinib. Vorapaxar The metabolism of Entrectinib can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Entrectinib can be decreased when combined with Voriconazole. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Entrectinib. Voxelotor The serum concentration of Entrectinib can be increased when it is combined with Voxelotor. Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Entrectinib. Warfarin The metabolism of Entrectinib can be increased when combined with Warfarin. Zafirlukast The metabolism of Entrectinib can be decreased when combined with Zafirlukast Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy This drug can harm a developing fetus. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Advise female patients of reproductive potential to use effective contraception during therapy and for at least 5 weeks after. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 3 months after. Lactation Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available The effects in the nursing infant are unknown. Because of the potential for adverse reactions in breastfed infants from this drug, advise lactating women to discontinue breastfeeding during therapy and for 7 days after. How should this medicine be used?

Entrectinib comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take entrectinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take entrectinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the capsules whole; do not open,…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)